Semaglutide
approvedAlso known as: Ozempic, Wegovy, Rybelsus, NN9535
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with approximately 94% structural homology to native human GLP-1. Its mechanism of action involves binding to and activating GLP-1 receptors in pancreatic beta cells, leading to glucose-dependent insulin secretion, suppression of glucagon release, and delayed gastric emptying. Additionally, central GLP-1 receptor activation in the hypothalamus reduces appetite and food intake, contributing to weight loss. The molecule is engineered with a fatty acid side chain that facilitates albumin binding, extending its half-life to approximately one week for subcutaneous formulations (Ozempic, Wegovy) and enabling once-daily oral administration (Rybelsus) via an absorption enhancer. Key research findings from over 4,800 PubMed-indexed studies demonstrate robust efficacy in glycemic control and weight management. The SUSTAIN and PIONEER trials showed significant reductions in HbA1c (1.0–1.8%) and body weight (4–15%) compared to placebo and active comparators. The SELECT trial (2023) further established cardiovascular benefits, with a 20% reduction in major adverse cardiovascular events in overweight or obese patients without diabetes. Semaglutide also improves non-alcoholic steatohepatitis (NASH) markers and reduces inflammation, though long-term safety data continue to accumulate. Clinically, semaglutide is approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy) in adults with obesity or overweight with comorbidities. Dosing is titrated to minimize gastrointestinal side effects (nausea, vomiting, diarrhea), which occur in up to 40% of patients but typically subside. Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Ongoing research explores its potential in heart failure, chronic kidney disease, and addiction disorders. For research purposes only — not medical advice.
Key data
C187H291N45O59Research & studies
Mean HbA1c reductions at week 52 were -1.71% (orforglipron 12 mg), -1.91% (orforglipron 36 mg), -1.23% (semaglutide 7 mg), and -1.47% (semaglutide 14 mg) from a baseline of 8.3%.; Orforglipron 12 mg and 36 mg were non-inferior and superior to semaglutide 7 mg and 14 mg, including orforglipron 12 mg versus semaglutide 14 mg (estimated treatment difference -0.24%, p=0.0050).; Gastrointestinal adverse events were more frequent with orforglipron (59% on 12 mg, 58% on 36 mg) than semaglutide (37% on 7 mg, 45% on 14 mg), mostly mild to moderate.; Discontinuations due to adverse events (9-10% vs 4-5%) and mean pulse rate increases (3.7-4.7 bpm vs 1.0-1.5 bpm) were higher with orforglipron than oral semaglutide.
After 1 year, mean weight loss was 14.6 kg (14.1%) with semaglutide 2.4 mg and 17.2 kg (16.5%) with tirzepatide.; Baseline characteristics were descriptively similar between groups (mean age ~48-50 years, ~78-80% female, mean weight ~105 kg).; 83.5% of semaglutide patients reached the maximum 2.4 mg dose, while 25.9% of tirzepatide patients reached the maximum 15 mg dose.; Both medications resulted in clinically meaningful weight loss after 1 year in patients with overweight or obesity without type 2 diabetes.
Semaglutide and tirzepatide each reduced the primary composite endpoint by more than 40% compared with sitagliptin.; Tirzepatide did not show a meaningful risk reduction over semaglutide (HR 0.86, 95% CI 0.70-1.06).; Results were consistent across negative controls, secondary endpoints, subgroups, and sensitivity analyses.; No substantially increased risk was observed for select safety endpoints.
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI, and HbA1c versus semaglutide 2.4 mg.; Tirzepatide 15 mg showed statistically significant greater odds of achieving 5% and 15% weight reduction and improvements in waist circumference, fasting plasma glucose, and triglycerides.; Both tirzepatide doses had non-significant trends toward greater improvements in HDL, LDL, systolic and diastolic blood pressure, and a generally comparable safety profile to semaglutide.; This is the first indirect comparison of tirzepatide and semaglutide specifically in patients with type 2 diabetes and overweight or obesity.
Semaglutide improved histological markers of fibrosis and inflammation in two preclinical MASH models.; Hepatic expression of fibrosis-related and inflammation-related gene pathways was reduced by semaglutide.; 72 serum proteins were significantly associated with MASH resolution and semaglutide treatment in a clinical trial.; The same 72 proteins were differentially expressed in MASH patients versus healthy individuals in an independent cohort.
A 44-year-old woman developed liver injury with elevated liver enzymes after semaglutide initiation for weight management.; Liver enzymes normalized after stopping semaglutide and worsened on rechallenge, confirming drug-induced liver injury.; A literature review of all reported semaglutide-related liver injury cases was included.; Diligent liver function monitoring is needed in patients taking semaglutide.
In type 2 diabetes, semaglutide reduced major adverse cardiovascular events by 26% (SUSTAIN-6) and major kidney disease events by 24% (FLOW).; In overweight or obese individuals with cardiovascular disease, semaglutide reduced major adverse cardiovascular events by 20% (SELECT) and slowed kidney function loss.; Semaglutide alleviates heart failure symptoms and reduces hospitalizations in obese individuals regardless of diabetes status.; Semaglutide's real-world use supports its safety and effectiveness across diverse patient groups, with a generally favorable safety profile.
Semaglutide enhanced cardiac function recovery and reduced fibrosis in the mouse I/R model.; Semaglutide mitigated oxidative stress and inhibited ferroptosis in cardiomyocytes.; RNA sequencing identified S100A9 as the target gene of semaglutide in protecting against MIRI.; In vitro, semaglutide decreased S100A9 expression by activating the PKC pathway, inhibiting cardiomyocyte ferroptosis.
Frequently asked questions
What is Semaglutide?
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with approximately 94% structural homology to native human GLP-1. Its mechanism of action involves binding to and activating GLP-1 receptors in pancreatic beta cells, leading to glucose-dependent insulin secretion, suppression of glucagon rel
How does Semaglutide work?
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
What is the research status of Semaglutide?
Semaglutide is currently classified as approved, with 5,757 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Semaglutide?
The reported half-life of Semaglutide is ~7 days.
What is the molecular weight of Semaglutide?
Semaglutide has a molecular weight of approximately 4114 g/mol (formula C187H291N45O59).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Semaglutide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key